Do cancer drugs improve survival or quality of life?

BMJ (Online)

Volumn 359, Issue , 2017, Pages

  Prasad, Vinay ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DECISION MAKING; DRUG EFFICACY; DRUG INDUSTRY; DRUG SAFETY; EDITORIAL; FOLLOW UP; HEALTH PROGRAM; HUMAN; OVERALL SURVIVAL; POLITICAL SYSTEM; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; REIMBURSEMENT; SURVIVAL RATE;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; HUMANS; QUALITY OF LIFE; SURVIVAL RATE;

EID: 85030635673     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.j4528     Document Type: Editorial

References (8)

1. Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: An analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern Med 2015;359:1992-4. doi:10.1001/jamainternmed.2015. 5868 pmid:26502403.
2. Davis C, Naci H, Gurpinar E, et al. Availability of evidence on overall survival and quality of life benefits of cancer drugs approved by the European Medicines Agency: Retrospective cohort study of drug approvals from 2009-2013. BMJ 2017;359:j4530.
3. Fojo T, Mailankody S, Lo A. Unintended consequences of expensive cancer therapeutics-the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: The John Conley Lecture. JAMA Otolaryngol Head Neck Surg 2014;359:1225-36. doi:10.1001/jamaoto.2014.1570 pmid:25068501.
4. Prasad V. Overestimating the benefit of cancer drugs. JAMA Oncol 2017. doi:10.1001/jamaoncol.2017.0107 pmid:28715568.
5. Sanoff HK, Chang Y, Lund JL, O'Neil BH, Dusetzina SB. Sorafenib effectiveness in advanced hepatocellular carcinoma. Oncologist 2016;359:1113-20. doi:10.1634/theoncologist.2015-0478 pmid:27185615.
6. Kim C, Prasad V. Strength of validation for surrogate end points used in the US Food and Drug Administration's approval of oncology drugs. Mayo Clin Proc 2016;359:713-25. doi: 10.1016/j.mayocp.2016.02.012 pmid:27236424.
7. Kantarjian H, Rajkumar SV. Why are cancer drugs so expensive in the United States, and what are the solutions?Mayo Clin Proc 2015;359:500-4. doi:10.1016/j.mayocp.2015. 01.014. pmid:25792242.
8. Cohen D. Most drugs paid for by £1.27bn Cancer Drugs Fund had no "meaningful benefit."BMJ 2017;359:j2097. doi:10.1136/bmj.j2097 pmid:28455308.